FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:613-626 August 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Non-Hodgkin's lymphoma is the most common hematologic cancer in adults, with more than 66,000 incident cases anticipated in the United States in 2008.¹ Approximately 85% of non-Hodgkin's lymphomas in adults are of B cell origin.² Some B-cell non-Hodgkin's lymphomas are indolent, or slow-growing, yet incurable. In contrast, others are aggressive or very aggressive, and may be rapidly fatal, yet are often curable.

There has been a revolution in the treatment of B-cell non-Hodgkin's lymphomas, owing largely to the availability of therapeutic monoclonal antibodies. The concept that antibodies might be effective for the treatment of cancers originated more than a century . . . [Full Text of this Article]

Rationale for the Use of Monoclonal Antibodies in B-Cell Lymphomas

Mechanisms of Action

Resistance to Monoclonal Antibodies

Antiidiotype Antibodies

Rituximab for Follicular and Low-Grade Lymphoma

Antibodies as Maintenance Therapy

Chemoimmunotherapy for Diffuse Large-B-Cell Non-Hodgkin's Lymphoma

Combinations of Antibody Therapy and Chemotherapy in Mantle-Cell Lymphoma

Radioimmunotherapy

⁹⁰Y-Labeled Ibritumomab Tiuxetan

¹³¹I-Labeled Tositumomab

Toxicity of Radioimmunotherapy

Other Antibodies

Anti-CD20 Antibodies in Development

Alemtuzumab

Galiximab

Anti-CD40 Antibodies

Epratuzumab

Lumiliximab

Hu1D10

Other Antibody Approaches

Future Directions

Source Information

From the Division of Hematology-Oncology, Georgetown University Hospital, Washington, DC (B.D.C.); and the Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York (J.P.L.).

Address reprint requests to Dr. Cheson at Georgetown University Hospital, 3800 Reservoir Rd., NW, Washington, DC 20007, or at bdc4@georgetown.edu.

Related Letters:

Monoclonal Antibody Therapy and Non-Hodgkin's Lymphoma
Goldstein M. R., Mascitelli L., Pezzetta F., Marignani M., Angeletti S., Fave G. d., Cheson B. D., Leonard J. P.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:192-193, Jan 8, 2009. Correspondence

This article has been cited by other articles:

• Li, B., Zhao, L., Guo, H., Wang, C., Zhang, X., Wu, L., Chen, L., Tong, Q., Qian, W., Wang, H., Guo, Y. (2009). Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 114: 5007-5015 [Abstract] [Full Text]  
• Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., Chang, C.-H. (2009). CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114: 3864-3871 [Abstract] [Full Text]  
• Brusselle, G. G., Demoor, T., Bracke, K. R., Brandsma, C-A., Timens, W. (2009). Lymphoid follicles in (very) severe COPD: beneficial or harmful?. Eur Respir J 34: 219-230 [Abstract] [Full Text]  
• Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., Chang, C.-H. (2009). Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 113: 6161-6171 [Abstract] [Full Text]  
• Bomback, A. S., Derebail, V. K., McGregor, J. G., Kshirsagar, A. V., Falk, R. J., Nachman, P. H. (2009). Rituximab Therapy for Membranous Nephropathy: A Systematic Review. CJASN 4: 734-744 [Abstract] [Full Text]  
• Goldstein, M. R., Mascitelli, L., Pezzetta, F., Marignani, M., Angeletti, S., Fave, G. d., Cheson, B. D., Leonard, J. P. (2009). Monoclonal Antibody Therapy and Non-Hodgkin's Lymphoma. NEJM 360: 192-193 [Full Text]  
• Perosa, F., Favoino, E., Vicenti, C., Guarnera, A., Racanelli, V., De Pinto, V., Dammacco, F. (2009). Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes. J. Immunol. 182: 416-423 [Abstract] [Full Text]